Menezes Maria Clara Saad, Raheem Farah, Mina Lida, Ernst Brenda, Batalini Felipe
Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA.
Mayo Clinic Arizona, 5777 E. Mayo Blvd, Phoenix, AZ 85054, USA.
Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332.
Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are approved for carriers with HER2-negative breast cancer in the adjuvant setting with a high risk of recurrence as well as the metastatic setting. However, the indications for PARPi are broader for patients with other cancer types (e.g., prostate and ovarian cancer), involving additional biomarkers (e.g., , , and ) and genomic instability scores. Herein, we summarize the data on PARPi and breast cancer and discuss their use beyond carriers.
聚腺苷二磷酸核糖聚合酶（PARP）抑制剂（PARPi）已被批准用于复发风险高的HER2阴性乳腺癌辅助治疗以及转移性乳腺癌患者。然而，PARPi在其他癌症类型（如前列腺癌和卵巢癌）患者中的适应证更广泛，涉及其他生物标志物（如 、 和 ）以及基因组不稳定评分。在此，我们总结了PARPi与乳腺癌相关的数据，并讨论其在HER2阴性乳腺癌患者之外的应用。
